Skip to content

Analysis of Red Blood Cell Integrity and Efficiency of Recovery Using a Novel Surgical Sponge-Blood Recovery Device (ProCell)

Analysis of Red Blood Cell Integrity and Efficiency of Recovery Using a Novel Surgical Sponge-Blood Recovery Device (ProCell)

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05545930
Enrollment
20
Registered
2022-09-19
Start date
2022-09-20
Completion date
2026-07-01
Last updated
2026-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Recovery

Keywords

Open Heart Surgery, Heart Transplant, Lung Transplant, ProCell

Brief summary

The purpose of this research study is to compare two methods of recovering blood from surgical sponges used during heart and lung surgeries. The two methods are: 1) manually wringing sponges by hand, and 2) automated wringing sponges by an FDA approved suction device. Both methods are already in use in heart and lung surgeries at University Hospitals at the discretion of the surgeon.

Interventions

PROCEDUREHand Wrung

Hand wrung refers to manually wringing surgical sponges by hand.

ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).

Sponsors

ProCell Surgical Inc.
CollaboratorUNKNOWN
University Hospitals Cleveland Medical Center
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Masking description

Subjects will be blinded to the order of intervention.

Eligibility

Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

* Undergoing heart or lung transplant, redo sternotomy, aortic surgery, and/or multi-valve repairs/replacements; and * At University Hospitals Cleveland Medical Center.

Exclusion criteria

* Patients with known bleeding disorders, including disseminated intravascular coagulation (DIC), prothrombin deficiency, factor V deficiency, factor VII deficiency, factor X deficiency, factor XI deficiency (hemophilia C), Glanzmann disease, hemophilia A, hemophilia B, idiopathic thrombocytopenic purpura (ITP), and Von Willebrand disease (types I, II, and III); * Patients undergoing emergent or emergent salvage surgery; and * Patients actively participating in another clinical trial which could affect outcomes.

Design outcomes

Primary

MeasureTime frameDescription
Level of Plasma Free HemoglobinBaselineLevel of plasma free hemoglobin will be measured at baseline.
Change in Volume of BloodBaseline, Post-Processing (Up to 120 Minutes)Volume of blood will be measured at baseline and post-processing.

Secondary

MeasureTime frameDescription
Level of HaptoglobinBaselineLevel of haptoglobin will be measured at baseline.
Number of Fragmented Red Blood CellsBaselineNumber of fragmented red blood cells will be measured at baseline.
Time to Wring SpongesUp to 120 MinutesTime to wring sponges will be measured.
Change in Weight of Surgical SpongeBaseline, Post-Procedure (Up to 5 Minutes)Weight of surgical sponges will be measured at baseline and post-procedure.
Level of Lactate DehydrogenaseBaselineLevel of lactate dehydrogenase will be measured at baseline.

Countries

United States

Contacts

Primary ContactJessica Hungate, MD
Jessica.Hungate@UHhospitals.org216-844-3800

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026